Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc.

CDIO
Cardio Diagnostics Holdings, Inc.US flagNASDAQ Capital Market
1.96
USD
+0.04
- -
5.80MMarket Cap
Cardio Diagnostics Holdings, Inc.
CDIO
(NASDAQ Capital Market)

Recent

price

1.96

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
0.01
0.04
0.04
0.01
0.01
Revenue per Share
-1.91
-1.96
-45.29
-19.81
-9.35
-3.71
-2.57
Basic EPS, GAAP
-0.01
-2.2
-50.2
-15.29
-6.02
-3.51
-2.42
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.19
3.37
13.56
4.32
6.24
3.82
2.51
Book Value per Share
-0.44
2.43
12.43
3.54
5.78
3.34
2.18
Tangible Book Value per Share
- -
- -
- -
- -
1
2
3
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-68,862.15
-478,784.32
-42,440.43
-23,977.86
-43,737.46
-44,690.68
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-1
-5
-8
-8
-6
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-68,862.15
-490,630
-49,087.81
-24,028.24
-43,832.49
-44,771.83
Profit Margin (%)
- -
1
4
2
8
5
6
Working Capital
- -
- -
- -
1
- -
- -
- -
LT Debt
- -
1
4
3
10
7
7
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-109.97
-173.6
-230.77
-133.96
-78.62
-75.44
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
3
3
Market Capitalization
5
6
6

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6
8
6
Cash, Cash Equivalents & STI
5
7
6
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
427.37%
-27.04%
Free Cash Flow
- -
3,564.85%
13.87%
Net Income, GAAP
- -
142.21%
-22.49%
Sales/Revenue/Turnover
- -
- -
-57.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.93
-1.71
-1.73
- -
-9.35
2025
-0.97
-0.97
-0.98
- -
-3.71
2026
-0.63
-0.51
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) develops and commercializes AI-powered epigenetics-based clinical tests for cardiovascular disease prevention, early detection, and management. The company offers Epi+Gen CHD, a blood test assessing three-year risk for symptomatic coronary heart disease events including heart attacks; PrecisionCHD, an integrated epigenetic-genetic blood test for coronary heart disease detection; Actionable Clinical Intelligence, a platform providing personalized epigenetic and genetic insights for chronic care management linked to Epi+Gen CHD and PrecisionCHD; Cardiovascular Risk Intelligence, a platform for healthcare stakeholders including providers, employers, brokers, benefits consultants, and government entities; and a research-use-only platform supporting biopharmaceutical discovery, development, and validation for cardiovascular diseases. Founded in 2017 and headquartered in Chicago, Illinois, Cardio Diagnostics operates in the United States, targeting healthcare providers, patients at risk for coronary heart disease, stroke, heart failure, and related comorbidities. Recent developments include partnerships with 15 new provider organizations across Northeast, South, Midwest, and West regions in October 2025 to expand adoption of Epi+Gen CHD and PrecisionCHD; and receipt of final Medicare gapfill payment rates of $854 for both tests from CMS in December 2025, effective January 1, 2026, up from preliminary rates of $350 and $684.76.

Company News

  • Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Shares Shorted: Short Interest Down 77.7% in September

  • Cardio Diagnostics Holdings, Inc. (CDIO) Shareholder/Analyst Call Prepared Remarks Transcript

  • Cardio Diagnostics (NASDAQ:CDIO) & Sutro Biopharma (NASDAQ:STRO) Head-To-Head Analysis

  • Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

  • Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

  • Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript

  • Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

  • Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026

  • Atlas Healthcare Physicians to Cover Cardio Diagnostics' Precision Cardiovascular Medicine Tests Across Its Network

  • Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June

  • IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Meesha Dogan, CEO of Cardio Diagnostics Holdings Inc.

  • CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026

  • Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

  • Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Cardio Diagnostics (NASDAQ:CDIO)

  • Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India

  • Cardio Diagnostics Holdings, Inc. and Southdale YMCA Announce New Heart Health Partnership to Serve the Edina, Minnesota Community

  • Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)

  • Cardio Diagnostics Holdings, Inc. to Present Data Demonstrating PrecisionCHD's Ability to Detect INOCA and MINOCA at the American Heart Association Scientific Sessions

  • NCH Becomes First U.S. Hospital to Use AI That Detects Hidden Heart Attack Risk a Decade in Advance

  • Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community